Dr Koudinov: I don't believe Alzheimer's Association dissapointed of Phase III clinical trial (of anti-amyloid Semagacestat by Eli Lilly) halt!

"The Alzheimer's Association is disappointed to learn of the negative interim results from the Phase III clinical trial of Semagacestat," William Thies, Ph.D., Alzheimer's Association Chief Medical and Scientific Officer says in a Press Release.

Comment by Alexei Koudinov follows:

Are they truly dissapointed at Alzheimer's association of Phase III clinical trial of Semagacestat by Eli Lilly? I doubt it! Or more precisely, I do not believe it! I mean I don't believe he is dissapointed of the development setback, as media reports. Perhaphs he is dissapointed of fundraising problem (as it will be much harder to full the public that the research funded by Alzheimer's association is just bullshit), meaning less profit personally for him? You can ask him and Alzheimer's association CEO, they should be available via Alz.Org web site. I tried myself. In April 2004 I wrote the letter to the editor of The Wall Street Journal on WSJ coverage of Alzheimer's research. There were two (plus letters to editor, and another article in late summer, after Alzheimer's Global convention) articles, and the person behind that research by WSJ's Sharon begley was myself: I brought the story to them, described facts, provided contacts, you will learn all this at Alzheimer's Code History web site. My letter to WSJ editor responded on Alzheimer's Association letter (by Sheldon Goldberg, President and CEO, Alzheimer’s Association, 16 April 2004) to The Wall Street Journal editor on April 16 WSJ article "Scientists World-Wide Battle a Narrow View of Alzheimer's Cause" by Sharon Begley. In this letter I provided facts why Alzheimer's asscoation is a part of narrow amyloid view on Alzheiemr's. And now Dr.Thies says he is dissapointed. I don't believe him, period.

Read the Press release by Alzheimer's Association